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ABSTRACT  
Bio-isosteric replacement is a frequently used tool in medicinal chemistry. Whilst the 
pharmacological activity is not influenced by the exchange of substituents, the solid-state 
characteristics and formation of different crystal forms may well be altered dramatically, 
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jeopardising the processability and safety of the drug compound. In this study we investigate a 
series of triphenylimidazole (TPI) derivatives as model compounds with the bio-isosteric 
exchange of only one halogen position (F, Cl, Br, I). Crystallisation from two industrially used 
solvents (methanol and acetonitrile) reveals solvate formation of all TPIs, for which the basic 
hydrogen bonded motif does not change. The three-dimensional packing depends on the size of 
the substituent and changes from fluoro- to chloro- and bromo-substitution but remains the same 
for the larger iodo-substituent. From acetonitrile, only F-TPI and Cl-TPI form an isomorphic 
channel solvate, which in both cases desolvates reversibly to an isomorphic crystal form. Due to 
the halogen atom lining of the channels, bromine and iodine are too large to generate a stable 
packing. This study illustrates the importance of understanding the influence of bio-isosteric 
substitution on the solid-state, in order to best utilize this common tool. 
Introduction 
The development of new pharmaceutical compounds to treat emerging and pandemic diseases 
such as ebola or long-standing problems such as bacterial infections is amongst the key topics of 
pharmaceutical research. It demands a steady stream of novel pharmaceutical compounds to 
tackle the disease in question. One of the tools used in the area of medicinal chemistry is bio-
isosteric replacement, which is the replacement of substituents of a lead molecule with other 
chemical groups without changing the overall biological activity.1, 2 This enables the medicinal 
chemist to improve specific properties, such as solubility, crystallinity, metabolic stability etc., 
which subsequently will improve the overall processability of the new drug compound. This 
concept has been applied to as diverse drug classes as cannabinoids3 and HIV antivirals.4 The 
selection of replacement groups is nowadays heavily helped by in silico studies and property 
predictions.5-7 
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Even though this approach has been used for over 60 years,8 the implications of bio-isosteric 
replacements of substituents, which sometimes differ vastly in size and/or electronics, on the 
crystallisation properties of the new molecule have been widely ignored. Small organic 
molecules show a high probability of crystallising in multiple crystal forms, which may differ in 
physico-chemical characteristics such as melting point or solubility.9-12 The latter characteristic is 
especially important for pharmaceuticals, as solubility and especially water solubility is directly 
linked to bioavailability of the drug compound and thus its pharmacological activity in patients. 
In addition to crystal forms that contain the desired molecule, solvates incorporate solvent 
molecules from the crystallisation process.13 Solvates can be interpreted as intermediates formed 
during the crystallisation process,14, 15 and can introduce traces of unwanted solvent into the 
pharmaceutical product, which can prove harmful or toxic to the patient. Thus, the levels of 
residual solvent in these applications are regulated.16 On the other hand, solvates represent a 
route to obtain novel unsolvated crystal forms, which are not accessible by direct 
crystallisation.17-22  
The inclusion of solvent molecules into crystal forms has been widely studied, not only in the 
pharmaceutical field. The influence of solvate formation has been studied in a co-crystal system 
that has been crystal-engineered to undergo photodimerisation. It was found that the inclusion of 
acetonitrile leads to a molecular arrangement allowing photodimerisation, whilst the methanol 
solvate hinders this.23 In other studies, inclusion has been utilised to separate xylenes24 showing a 
clear preference of one guest over another, 25 or to store volatile guests.26, 27 Inclusion complexes 
have recently become focus of attention to study the incorporated molecules, either in an unusual 
conformation,28 or to obtain structural information of a hard to crystallise compound.29, 30 
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Considering the variation in size and interaction potential in bio-isosteric groups, the choice of 
replacement group will influence the crystal structure of the substances, as has recently been 
shown for a series of trityl compounds.31 In addition, change of halogen substituents from chloro 
via bromo to iodo on phloroglucinol has been shown to influence the incorporation mode of 
water into the crystal structure.32 We are thus systematically investigating the influence that the 
change of only one substituent has on the crystallisation behaviour and polymorphism of model 
compounds.33 In order to reduce the possibility of strong interactions between the molecules, we 
use 2,4,5-triphenylimidazoles (lophine, TPI, Figure 1) as our model, which can only donate and 
accept one hydrogen bond and show thus a reduced complexity compared to pharmaceutically 
used compounds. Lophine derivatives are used as core structures in medicinal chemistry,34 as 
well as for photophysical applications.35-37 
During our work on the polymorphism of halogenated TPIs, we investigated a series of 2-(4′-
p-X-phenyl)-4,5-diphenylimazoles (X-TPI; X = F, Cl, Br, and I). These substituents are 
frequently exchanged for bio-isosteric replacement,38 and do not significantly change the overall 
electronics of the resulting compounds. However, the substituents vary considerably in size, with 
F having the smallest van-der-Waals radius with 1.47 Å, Cl with 1.75 Å, Br with 1.85 Å to I with 
1.98 Å. In the present study we report our results of crystallisation experiments with two 
standard solvents, methanol and acetonitrile, which are frequently used in pharmaceutical 
processes. 
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Figure 1. Molecular structure of 2,4,5-triphenylimidazole (TPI) derivatives (lophines) used in 
this study. 
Experimental section 
Materials 
Benzil, p-halogenbenzaldehyde (F, Cl, Br, I), ammonium acetate, potassium carbonate and all 
organic solvents were purchased from Sigma Aldrich and used without further purification. 
Methods 
Synthesis 
All TPIs were synthesised using the literature method.39 Equimolar amounts of benzil and 
substituted benzaldehyde were suspended in acetic acid with 10-fold amount of ammonium 
acetate. The suspension was then heated in a microwave to 180 °C for 5 min and cooled to room 
temperature. The resulting solution was then poured into ice water and neutralised with K2CO3 
forming a beige precipitate. This was collected by filtration and washed with H2O before 
recrystallisation. 
Crystallisation methods 
Approximately 10 – 20 mg compound was used in each crystallisation experiment. For slow 
cooling and fast cooling experiments, sufficient solvent was added to produce a hot-saturated 
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solution. These were then left to cool to room temperature in an insulating wooden block (slow 
cooling) or quenched in an ice and water bath (fast cooling). For evaporation, the material was 
dissolved in sufficient solvent to produce an undersaturated solution at room temperature and let 
stand to evaporate. Precipitation was conducted by producing a hot saturated solution and adding 
at least double the volume of cold (room temperature) diethyl ether as anti-solvent. The crystals 
forming were immediately removed from solution in case of the fast cooling and precipitation 
experiments, whilst evaporation and slow cooling experiments were left for one day before 
analysis. 
Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was performed with a Q2000 (TA instruments, New 
Castle, DE, USA). Approximately 1 to 3 mg of sample were accurately weighed (microbalance, 
Sartorius, Göttingen, Germany) into sealed Al pans and submitted to a ramp scan in the range 
from 25 to 370 °C with a heating rate of 10 °C min-1. Dry nitrogen was used as the purge gas 
(purge: 50 mL min-1). The instrument was calibrated for temperature and energy in the respective 
temperature range with pure indium (purity 99.999%, m.p. 156.6 °C, heat of fusion 28.45 J g-1). 
Thermogravimetric analysis 
Measurements were performed with a Q500 thermogravimetric system (TA instruments, New 
Castle, DE, USA). Samples of approximately 2 to 6 mg were accurately weighed into 50 μl 
platinum pans and subjected to non-isothermal TGA at a heating rate of 10 °C min-1. Nitrogen 
was used as purge gas at a purging rate of 60 ml min-1. 
X-ray diffractometry  
Powder X-ray diffraction patterns were recorded using an Empyrean diffractometer (Panalytical, 
Almelo, Netherlands) in Bragg-Brentano geometry with Cu-Kα radiation, graphite 
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monochromator, 0.2 mm fixed Soller slits and PIXcel detector. The X-ray tube was operated at 
40 kV and 40 mA, while the samples were prepared on a low-background silicone slide sample 
holder as dry powder. 
Single crystals of F-TPI and Br-TPI methanol solvates were picked, coated in perfluoro 
polyether oil and mounted on MiTeGen sample holders. These were placed directly into a pre-
cooled cryostream on a Bruker (Karlsruhe, Germany) D8 Quest diffractometer using Mo-Kα 
radiation (0.71073 Å). Single crystals of Cl-TPI acetonitrile solvate were picked, coated in 
perfluoro polyether oil and mounted on MiTeGen sample holders. The diffraction experiment 
was carried out on a Rigaku (Sevenoaks, UK) Saturn 724+ diffractometer at Station I19 of the 
Diamond Light Source synchrotron (undulator, λ = 0.6889 Å, ω-scan, 1.0° per frame). The data 
from a 4-component non-merohedral twin were processed using Bruker Apex-II software, 
deconvoluted using CELL_NOW40 and corrected for absorption using TWINABS 2012/1.41 The 
structure was solved using Olex.solve42 and refined using ShelXL.43 All non-hydrogen atoms 
could be located from Fourier difference maps and were refined anisotropically. Hydrogen atoms 
were calculated as geometrical riding models on the heavy atom and refined isotropically. 
Results and discussion 
Methanol solvates 
Crystallisation of all TPI derivatives from methanol yielded a crystal form containing solvent 
from crystallisation. The analysis of the respective TG thermograms (Figure 2a) reveals a weight 
loss corresponding to 1 mol methanol per mol TPI (Table 1) for all crystal forms. The weight 
loss of F-TPI starts almost immediately with a slow zero-order loss of solvent, which is most 
likely the evaporation of trapped and surface-bound solvent. The weight loss speeds up at 
temperatures above 60 °C resulting in a one-step solvent release. The solvates of Cl-, Br- and I-
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TPI show slightly higher stability with the start of the weight loss not below 70 °C. Cl-TPI 
shows a single mass loss step comparable to F-TPI, whilst Br-TPI and I-TPI show multiple steps. 
All desolvation events are in the same temperature range as the boiling point of methanol, which 
indicates the high stability of these crystal forms. 
The corresponding DSC thermograms (Figure 2b) show the desolvation as endothermic events 
in temperatures regions comparable to those detected by TG. Interestingly, Br-TPI and I-TPI 
show double peaks, which might be due to partial desolvation followed by melting of the 
remaining intact solvated crystal form, i.e. passing of the peritectic. This observation fits well 
with the two-step desolvation detected by TG. All TPI solvates desolvate into a stable crystalline 
form, which melts at temperatures above 250 °C. 
 
Figure 2. Thermoanalytical data of the four TPI methanol solvates: a) TG thermograms and b) 
DSC thermograms. 
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Table 1. Weight loss of the methanol solvates as determined by TG analysis 
 Weight loss weight loss molar calc. weight loss melting unsolvated  
 range [°C] [%] ratio monomolar [%] form (onset) [°C] 
F-TPI 52 - 92 9.31 1.007 9.250 252.9 
Cl-TPI 70 - 102 8.42 0.949 8.831 262.7 
Br-TPI 70 - 118 8.32 1.063 7.867 261.2 
I-TPI 73 - 100 6.80 0.962 7.053 268.0 
The methanol solvates of F-TPI and Br-TPI could be crystallised in sufficient quality to obtain 
single crystal structures. The crystallographic data of these two crystal forms are listed in Table 
2. Whilst the most common packing motif of imidazole derivatives is the hydrogen bonded 
chain,35, 44 this motif is broken in the case of the methanol solvates. In both crystal forms, the 
methanol molecule intercalates into the chains accepting one hydrogen bond from one imidazole 
and donates a second to the next imidazole (Figure 3a). The TPI molecules are oriented counter-
parallel whilst the chains show a zig-zag ribbon like conformation with the edge being formed by 
the methanol molecules (Figure 3b). These then stack on top of each other. The next stacks are 
connected through weaker C-H∙∙∙π interactions of adjacent non-substituted phenyl rings. Even 
though the bromine substituents are closer than twice their van der Waals radius (distance: 
3.5472(5) Å with 2 x vdW radius: 3.7 Å), the orientation of the TPI molecules and thus the 
geometry of the Br-Br interaction does not directly point towards halogen bonding and thus this 
interaction is less likely to be a driving force of this packing motif.  
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Figure 3. Molecular structure of Br-TPI methanol monosolvate: a) hydrogen bonded chains with 
intercalated methanol and b) stacking of the chains in the crystal structure, hydrogen atoms are 
omitted for clarity. Colour code: carbon (grey), hydrogen (light grey), nitrogen (blue), oxygen 
(red), bromine (brown). 
Interestingly, the packing of the stacks is different for F-TPI compared to Br-TPI. 
Whilst the fluoro-substituent is small enough to allow the phenyl rings to properly 
interlock giving a dense packing, the bromine atom is too large for this motif. This results 
in two distinct changes of the packing: firstly, adjacent layers in the crystallographic a-
direction of Br-TPI move further apart and secondly, the layers shift in the 
crystallographic b-direction of Br-TPI so that the bromine atoms orient along channels. 
This results in a higher symmetry of the crystal structure as well as a slightly different 
long range packing. Whilst F-TPI methanol solvate crystallises in identical layers, i.e. 
AAAA, Br-TPI methanol solvate shows alternating layers, i.e. ABAB, as can be seen by 
the shift in opposite directions of the Br-Br pairs (Figure 4). This correlation is 
reminiscent of polytypism, even though these two crystal forms change in their chemical 
entities (F vs. Br substitution) and thus the term ca, strictly speaking not be used.45 
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The crystallographic symmetry of the F-TPI methanol solvate generates disorder in the 
hydrogen bonded chains. The asymmetric unit contains three methanol molecules, of 
which two lie on special positions on the 2-fold axis. Thus, their OH-groups show 
disorder over two positions generating disorder in the position of the proton of the 
imidazole ring. Even though the third methanol molecule can be refined without disorder 
due to its general position, the hydrogen bonded chain forces its OH-group to be 
disordered as well. Since refinement of the structure in P1 resolves the disorder, it can be 
assumed that the crystallographic symmetry would be broken if hydrogen atom positions 
could be located accurately, e.g. by using neutron diffraction. 
 
Figure 4. Molecular packing in the methanol solvates of F-TPI vs. Br-TPI. 
Table 2. Crystallographic data of the methanol solvates of F-TPI and Br-TPI as well as the 
acetonitrile solvate of Cl-TPI as determined by X-ray single crystal diffraction. 
Crystal form F-TPI x MeOH Br-TPI x MeOH Cl-TPI x AcN 
Formula C21H15N2F x CH4O C21H15N2Br x CH4O C21H15N2Cl 
    x 0.25 C2H3N 
Mr (g mol-1) 346.39 407.31 341.06 
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Crystal system monoclinic monoclinic monoclinic 
Spacegroup P2 P21/c Pn 
T (K) 120 120 100 
a (Å) 13.164(1) 5.9477(3) 8.854(1) 
b (Å) 5.9105(6) 11.6799(7) 19.875(3) 
c (Å) 23.800(2) 27.003(2) 19.924(3) 
α 90 90 90 
β 104.421(3) 91.541(2) 93.712(2) 
γ 90 90 90 
V (Å3) 1793.4(3) 1875.2(2) 3498.6(9) 
Z 4 4 8 
Density (calc, g cm-3) 1.283 1.443 1.295 
Abs coeff. (mm-1) 0.087 2.205 0.208 
F(000) 728 831 1420 
Crystal size (mm3) 0.237 x 0.231 0.619 x 0.188 0.5 x 0.02  
 x 0.12 x 0.093 x 0.02 
Θ range for 2.066 – 25.999 1.90 – 26.00 0.993 – 24.415 
data collection 
Index ranges -15 ≤ h ≤ 15 -7 ≤ h ≤ 7 -10 ≤ h ≤ 10 
 -7 ≤ k ≤ 7 -14 ≤ k ≤ 14 -23 ≤ k ≤ 23 
 -29 ≤ l ≤ 29 -34 ≤ l ≤34 -23 ≤ l ≤ 23 
Reflections col. 20125 51111 34297 
Independent refl. 7045 3697 34297 
Refinement method full-matrix least-squares on F2 
Data/restraints/ 7045/1/477 3697/0/236 34287/2/896 
parameter 
Goodness of fit on F2 1.021 1.0312 1.012 
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R indices [I>2σI] R1 = 0.0583 R1 = 0.0330 R1 = 0.0444 
 wR2 = 0.1091 wR2 = 0.1127 wR2 = 0.1043 
R indices (all data) R1 = 0.1137 R1 = 0.0427 R1 = 0.0509 
 wR2 = 0.1260 wR2 = 0.1255 wR2 = 0.1068 
Since only two of the four solvates could be crystallised for single crystal diffraction, it is 
difficult to make definite statements about the packing of the other two crystal forms. It can be 
assumed, however, that the hydrogen-bonded chains persist in all four crystal forms. This is 
corroborated by the very similar desolvation temperatures of all four crystal forms indicating that 
the desolvation process has a comparable activation energy, i.e. the energy necessary to break the 
interactions between the solvent and the host molecules. If the basic packing motif would change 
drastically between the four solvates, a wider variation of desolvation temperatures would be 
anticipated alongside different desolvation kinetics.  
The powder X-ray diffractograms of all four TPI derivatives show certain similarities (Figure 
5). Whilst Br-TPI and I-TPI can be regarded as isostructural, which can be detected as a shift of 
the peak positions without changing the overall pattern, there is no similarity between these two, 
F-TPI and Cl-TPI. It can thus be assumed that the packing of Br-TPI is the most efficient for the 
compounds with large substituents in this series, whilst the smaller ones can pack in different 
arrangements of the basic hydrogen bonded planes. 
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Figure 5. Powder X-ray diffractograms of the methanol solvates of the four TPI derivatives. 
Calculated patterns of the single crystal structures in light grey. 
Upon desolvation, all methanol solvates transform into an unsolvated crystal phase (Figure 6). 
All of these show low crystallinity and a comparably high amorphous background, but reveal 
distinctly different peak patterns and intensities proving them to be different crystal forms to the 
solvates. However, it can be observed that the desolvated crystal forms of F-TPI and Cl-TPI are 
isomorphous. This is surprising, as the methanol solvates were not structurally related. The Br-
TPI and I-TPI desolvated crystal forms, on the other hand, reveal no similarity in their 
desolvated modification unlike their methanol solvates. It can thus be assumed that the 
desolvation and concomitant reorganisation process is significantly influenced by the different 
sizes of the substituent and similar packing arrangements are not energetically preferable. 
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Figure 6. Powder X-ray diffractograms of the crystal forms after desolvation of the methanol 
monosolvates. 
Acetonitrile solvates 
Crystallisation of F-TPI from acetonitrile yielded a crystal form, which TG indicated to be a 
solvate (Figure 7a). The weight loss in the range from 60 to 150 °C of 3.194% corresponds well 
to a stoichiometry of a tetarto-solvate (0.25 mol acetonitrile to 1 mol F-TPI, calculated mass loss: 
3.162%), whilst the broad desolvation temperature range suggests slow desolvation kinetics. The 
corresponding differential scanning calorimetry (DSC) trace shows a well-matched desolvation 
endotherm in the same temperature range followed by a melting endotherm at 252.3 °C (onset) 
of the corresponding unsolvated crystal form.  
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Figure 7. TG and DSC thermograms of acetonitrile solvates of F-TPI and Cl-TPI. 
 
Figure 8. Powder X-ray diffractograms of the crystal forms crystallising from acetonitrile 
Changing the TPI substituent from fluorine to chlorine (vdW radius 1.47 Å to 1.77 Å) seems 
not to prevent the formation this solvate. Powder X-ray diffraction proved that the Cl-TPI solvate 
is isostructural to that of F-TPI (Figure 8). The thermal data of the Cl-TPI solvate (Figure 7b) 
shows a lower mass loss of 2.942%, as detected by TGA, which again corresponds to a tetarto 
solvate (calculated weight loss 3.009%). The desolvation is almost undetectable by DSC, which 
is probably due to the broad range of this event from 50 °C to almost 200 °C. The respective heat 
flow will be so low that it is almost indistinguishable from the baseline. However, a small but 
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reproducible endothermic peak can be detected from 150 to 167 °C, which is most likely 
connected to the desolvation event. Melting subsequently occurs at 262.5 °C. 
The change from chlorine to bromine (1.85 Å van-der-Waals radius) as the substituent proves 
too big a change for the acetonitrile solvate formation, and the resulting crystal form is 
unsolvated (Fig. S1). The X-ray powder pattern confirms the presence of a crystal form that is 
not structurally related to the acetonitrile solvates of F-TPI or Cl-TPI as observable by the 
distinctly different peak positions. The same is true for iodo-substituted TPI, which shows no 
detectable weight loss in the TGA measurements (Figure S2) and has distinctly different peak 
positions in the powder pattern. This I-TPI unsolvated crystal form shows no similarity to any of 
the other crystal forms from acetonitrile described above for the other halogens  
 
Figure 9.  Crystal  structure  of  Cl‐TPI  acetonitrile  solvate  along  the  crystallographic  a‐axis.  Hydrogen 
atoms  omitted  for  clarity,  atomic  displacement  ellipsoids  drawn  at  50%,  colour  code:  carbon  (grey), 
nitrogen (blue), chlorine (green). 
Although the investigated solvates of F-TPI and Cl-TPI show a strongly anisotropic crystal 
growth with a needle-shaped habit, we were able to solve the crystal structure of the Cl-TPI 
solvate on instrument I19 at the Diamond Light Source, Didcot, UK. The crystal form 
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crystallises in the monoclinic spacegroup Pn with four molecules of Cl-TPI and one molecule of 
acetonitrile in the asymmetric unit. The Cl-TPI molecules arrange in the well-reported infinite 
chains through hydrogen-bonding along the imidazole rings, which are oriented along the 
crystallographic a-axis and also along the preferred axis of growth (Fig. S3). In between four 
chains of host molecules are channels filled with the solvent, which again is oriented along the 
crystallographic a-axis (Figure 9). These channels are lined alternatingly with a ring of chlorine 
atoms and a layer of phenyl rings interacting with the nitrogen atom of the solvent through C-
H···N hydrogen bonds, which are generally regarded to be weak. The channels, however, are 
stabilised by Cl···Cl halogen bonds (Fig S4), 3.38-3.63 Å in length and at a bond angle of 155-
162°.  
The diameter of these pores is approximately 4.93 Å, which is only 1.39 Å more than double 
the van-der-Waals-radius of chlorine. This might explain the desolvation behaviour observed by 
TGA over a wide temperature range. The channels containing the acetonitrile have a comparable 
structure to a string of pearls, in which the pearls represent sufficient void space for acetonitrile 
to diffuse through (i.e. the spaces lined with phenyl rings), whilst the string spaces represent the 
constriction by the chlorine atoms. When looked at statically, the solvent molecule would not be 
able to diffuse through these channels and desolvation would be accompanied by destruction of 
the crystal structure and correlated pseudomorphosis (as seen for the methanol solvates) or at 
least cracking of the crystal in order to release the solvent. However, as has recently been shown 
for a porous organic cage structure, crystalline materials are not static and molecules within the 
structure can move around their position.46 The authors of this study show that certain gasses can 
induce a higher nominal porosity of the material by accessing void space within the structure that 
is only accessible for very short periods of time. 
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Since the F-TPI acetonitrile solvate shows an isostructural powder pattern to Cl-TPI, the 
crystal structure has the same string-of-pearls channels with constriction through the fluorine 
atoms. If we assume that the overall crystal structure does not change and the pore size stays 
approximately the same, the pore diameter would be approximately 2 Å more than the van-der-
Waals radius of the lining fluorine atoms, and thus present a smaller obstacle to the diffusion of 
acetonitrile through the pores. This explains the narrower temperature range of the desolvation 
observed by TGA, whilst the initial stability and higher onset temperature of the weight loss can 
be explained by the energy necessary to overcome the intermolecular interactions between the 
solvent and the host molecules in both cases. 
 
Figure 10. Powder X-ray patterns of acetonitrile solvates and respective desolvates of F-TPI and 
Cl-TPI.  
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Figure 11. Powder X-ray patterns of solvated, desolvated and resolvated acetonitrile solvate of 
F-TPI. 
In order to show the close relationship of the solvate to the respective desolvated crystal form 
of F-TPI and Cl-TPI, both solvates were desolvated by heating up to 190 °C using the TGA and 
following the weight change to ensure complete desolvation. PXRD analysis confirmed the 
presence of a new crystal form (Figure 11), which shows peak shift to higher angles and thus 
smaller d-spacings when compared to the original solvated crystal structure. Even though these 
shifts are comparably large, the overall powder patterns change little. As the solvated crystal 
forms, the desolvated forms of F-TPI and Cl-TPI are isostructural. Another indication of the 
isostructurality of both solvates with their respective desolvates is the absence of 
pseudomorphosis or a moving front indicating single-crystal to single-crystal transition during 
desolvation, as has been proven by thermo-microscopy. Final proof, however, would only be 
possible by indexing the powder pattern and solving the crystal structure, which is scope of 
ongoing work. If the two solvate/desolvate pairs are indeed isostructural, this would corroborate 
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our hypothesis of the solvent leaving the crystal structure by diffusion along the channels. 
Neither of the new crystal forms is related to those observed for Br-TPI or I-TPI.  
The unsolvated crystal forms were then stored in a saturated atmosphere of acetonitrile to 
probe the reversibility of the desolvation process (Figures 11 and S5). After seven days of 
storage, the PXRD pattern of the materials showed full resolvation to the acetonitrile solvates, 
whilst storage for a further five days only improves the crystallinity of the sample, as observed 
by the increased sharpness of the peaks. The resolvation upon exposure to saturated solvent 
atmosphere could be explained by at least partial retention of the porous structure in the 
desolvated crystal structure, which contracts in order to fill the voids and thus minimises the 
crystal lattice energy. This would facilitate the re-uptake of solvent without the necessity of a 
phase change. Such behaviour has been shown for pharmaceutical hydrates,47, 48 and can pose 
problems during manufacturing. In this case, the formation of an isostructural desolvate poses a 
way to generate a new anhydrous crystal form.17, 49  
Desolvation did not occur when the solvates were stored for 7 days under dry conditions 
(phosphorous pentoxide) at ambient temperature, which shows that a certain amount of 
activation energy is necessary to start the desolvation. However, storing the solvate at ambient 
conditions, i.e. at approximately 50% relative humidity at 23 °C, led to a transition to the 
desolvate over a period of two weeks. It is thus likely that water plays an important role in the 
desolvation of these solvates, and this is the focus of on-going studies. 
Unsolvated crystal forms 
Each of the TPI derivatives shows two unsolvated crystal forms, either from desolvation of the 
solvates or, in the case of Br-TPI and I-TPI, by direct crystallisation from acetonitrile (Fig S6). 
The F-TPI and Cl-TPI desolvates from both solvates are the same modification. This is 
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surprising, as it has been shown above that the acetonitrile solvate and its desolvate are related or 
even isostructural. It can be assumed that in this case, the desolvate is so stable that it forms 
during the pseudomorphosis and connected reorganisation of the crystal lattice upon release of 
methanol from the methanol solvate. In the case of Br-TPI, the desolvate of the methanol solvate 
results in a different crystal form than direct crystallisation from acetonitrile. This shows the 
significance of using solvate formation during crystal form discovery, as has been frequently 
shown for organic compounds.17, 20, 47, 49 I-TPI results in the same crystal form independent from 
the solvent/solvate, which again points towards one energetically favoured modification.  
Even though this study shows clearly the influence the simple exchange of one substituent has 
on the crystallization characteristics of the resulting compounds, the data presented here are only 
the early stage of the investigation and more information is needed to draw definite conclusions 
of the substituent influence on the solid-state behaviour. What is blatantly clear is that the simple 
exchange of a halogen substituent on a simple model compound with reduced complexity can 
significantly influence the solid-state landscape and the crystal forms available. Whilst the 
change from fluorine to chlorine seems to have less of an effect, exchanging chlorine with 
bromine effects a more radical change in the solid-state behaviour. The iodo-substituent then 
follows the behavior of bromine. 
Conclusion 
In conclusion, we have reported the solvate formation of a series of bio-isosterically substituted 
triphenylimidazoles (2-(4′-p-X-phenyl)-4,5-diphenylimazoles, X-TPI; X = F, Cl, Br, and I) in 
two industrially used solvents, methanol and acetonitrile. There is a clear difference of solvate 
formation depending on the size of the substituent as well as the incorporation motif of the 
solvent. Methanol intercalates into the characteristic hydrogen-bonded imidazole chains, a motif 
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that most likely persists independently from the substituent. However, whilst the packing in two 
dimensions stays the same, the substituent’s size has an influence on the packing in the third 
dimension. Solvate formation from acetonitrile can only be observed for the smaller halogen 
substituents (F-TPI and Cl-TPI), which form a channel solvate that can be desolvated and 
resolvated, apparently without changing the overall crystal structure. Since the channels are lined 
with the halogen substituent, bromine and iodine substitution proves to be too much of a steric 
hindrance for the packing to be stable, and thus Br-TPI and I-TPI crystallise in non-solvated 
crystal forms. Two different unsolvated crystal forms can be obtained for Br-TPI by desolvation 
of the solvates or direct crystallisation from acetonitrile, whilst F-TPI, Cl-TPI and I-TPI 
crystallise in the same unsolvated crystal form. Overall, there seems to be related behavior 
between fluoro- and chloro-substitution as well as bromo-and iodo-substitution with little 
correlation between chloro- and bromo-substitution. This is an interesting finding and should be 
verified with additional data. 
Investigation of this series of model compound for bio-isosteric replacement with reduced 
complexity shows the significant influence of the size of the substituent on the crystallisation of 
different modifications. Whilst this can be a big advantage to engineer the appropriate crystal 
form or particle size, e.g. through desolvation and correlated pseudomorphosis, it can also pose 
the problem of residual solvent or unwanted solvate formation and thus increase the number of 
processing steps needed. It is clear from this study that the simple exchange of one substituent 
for its bio-isostere can have massive influence on the solid-state properties of a compound and 
that more research into this field is needed. 
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